The Canadian Rett Syndrome Coalition - comprising the Rett Syndrome Society of British Columbia (RSSBC), Rett Syndrome Society of Alberta (RSSA), Saskatchewan Rett Syndrome Association (SRSA), ...

Research from the University of Gothenburg, Sweden, clarifies the complex interaction between gut bacteria and irritable ...

NEW YORK – Taysha Gene Therapies has regained full rights to its lead program, TSHA-102, for Rett syndrome after an option agreement with Astellas expired.

Recently, Taysha Gene Therapies announced it has regained full rights to its lead gene therapy candidate TSHA-102 for Rett syndrome after the expiration of an option agreement with Astellas, following ...

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for ...

The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...

I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic fle ...

Taysha Gene Therapies ( ($TSHA) ) has provided an announcement. On October 16, 2025, Taysha Gene Therapies announced it has regained full rights ...

Taysha Gene Therapies has regained full rights to TSHA-102, its program that is in clinical evaluation to treat the neurodevelopmental disease Rett syndrome.

The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...

An announcement from Neurogene ( ($NGNE) ) is now available. On October 9, 2025, Neurogene Inc. announced the completion of discussions with the ...